FNDX vs IBB
Schwab Fundamental US Large Company Index ETF vs iShares Biotechnology ETF
- • FNDX has the lower expense ratio at 0.25% vs 0.44% for IBB.
- • FNDX pays a higher dividend yield (1.44%).
Side-by-side metrics
| Metric | FNDX | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.25% | 0.44% |
Dividend yield Trailing 12-month yield. | 1.44% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $28.47B | $11.50B |
YTD return | 21.76% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.78 | 0.60 |
P/E ratio | 19.05 | 25.48 |
Last price | $32.96 | $217.75 |
Inception | — | — |
Issuer | Schwab | iShares |
FNDX top holdings
| AAPL | Apple Inc | 4.84% |
| MSFT | Microsoft Corp | 3.14% |
| XOM | ExxonMobil Holdings Corp | 2.63% |
| BRK-B | Berkshire Hathaway Inc Class B | 1.83% |
| AMZN | Amazon.com Inc | 1.80% |
| CVX | Chevron Corp | 1.77% |
| JPM | JPMorgan Chase & Co | 1.55% |
| META | Meta Platforms Inc Class A | 1.51% |
| UNH | UnitedHealth Group Inc | 1.44% |
| GOOGL | Alphabet Inc Class A | 1.40% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About FNDX
FNDX (Schwab Fundamental US Large Company Index ETF) is US large caps weighted by fundamental factors. Managed by Schwab, the fund carries $28.5B in assets under management, an expense ratio of 0.25%, a dividend yield of 1.44%. Its largest holding is Apple Inc (AAPL), which represents 4.8% of the portfolio. Real Estate is the fund's largest sector exposure at 1.8%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.